A meta-analysis of GLP-1 after Roux-en-Y gastric bypass: impact of surgical technique and measurement strategy
[1] This means patients can use any of the approved sites without needing to adjust their dose or timing
Our clinical experience shows these medications are changing health outcomes for individuals facing weight-related medical conditions
Protein shakes can be an especially good option since they are already partially broken down and move through the stomach more easily
A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes
That dynamic shifted in 2024, when Wegovy gained an indication for reduced cardiovascular risk in March and Zepbound added an OSA indication in December
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
